Samabriva Biotechnology is pioneering a novel approach to biopharmaceutical and chemical production through its innovative use of plant-based systems, specifically utilizing hairy root cultures. This technology allows for the efficient and scalable production of high-value molecules, including natural active compounds and recombinant proteins, in a controlled environment. The hairy root system is advantageous due to its ability to grow independently of the plant's green parts, thrive in bioreactors without the need for light or heat, and maintain a stable production process year-round. This method not only enhances yield and consistency but also significantly reduces the risks associated with traditional animal-based production, such as virus and prion transmission.

The company's platform is designed to be adaptable and cost-effective, offering continuous and reproducible production capabilities. Samabriva's expertise extends across the entire value chain, from genetic engineering to large-scale bioreactor production, ensuring that they can meet diverse bioproduction needs. Their focus on optimizing metabolic pathways and employing advanced techniques like Design of Experiment (DoE) allows for the efficient development of high-yield plant clones. This comprehensive approach positions Samabriva as a leader in the biopharmaceutical and active pharmaceutical ingredient (API) markets, providing clients with reliable and innovative solutions for their production challenges.

France

Samabriva Biotechnology is a company that is creating a new method for producing biopharmaceuticals, chemicals, and biotech products using plants. Samabriva’s flexible platform combines the benefits of plant-based systems and traditional biomanufacturing techniques. By developing and cultivating high-yield plant clones in large-scale bioreactors it is possible to produce large quantities of high-value products more efficiently than traditional manufacturing methods.

Samabriva

Company Details